DrugPatentWatch Database Preview
Details for Patent: 5,852,195
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which drugs does patent 5,852,195 protect, and when does it expire?
Patent 5,852,195 protects APTIVUS and is included in two NDAs.
Protection for APTIVUS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-two patent family members in thirty-one countries.
Summary for Patent: 5,852,195
| Title: | Pyranone compounds useful to treat retroviral infections |
| Abstract: | The present invention relates to compounds of formulae (I) and (II) which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl[b]pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus, wherein R.sub.10 and R.sub.20 taken together are formulae (III) and (IV). ##STR1## |
| Inventor(s): | Romines; Karen Rene (Paw Paw, MI), Bundy; Gordon L. (Portage, MI), Schwartz; Theresa M. (Kalamazoo, MI), Tommasi; Ruben A. (Whitehouse Station, NJ), Strohbach; Joseph W. (Mendon, MI), Turner; Steven Ronald (Kalamazoo, MI), Thaisrivongs; Suvit (Kalamazoo, MI), Aristoff; Paul Adrian (Kalamazoo, MI), Johnson; Paul D. (Portage, MI), Skulnick; Harvey Irving (Kalamazoo, MI), Skaletzky; Louis L. (Kalamazoo, MI), Anderson; David John (Kalamazoo, MI), Morris; Joel (Kalamazoo, MI), Gammill; Ronald B. (Portage, MI), Luke; George P. (Lexington, MA) |
| Assignee: | Pharmacia & Upjohn Company (Kalamazoo, MI) |
| Application Number: | 08/809,224 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 5,852,195
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | APTIVUS | tipranavir | CAPSULE;ORAL | 021814-001 | Jun 22, 2005 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| Boehringer Ingelheim | APTIVUS | tipranavir | SOLUTION;ORAL | 022292-001 | Jun 23, 2008 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 5,852,195
| PCT Information | |||
| PCT Filed | May 04, 1995 | PCT Application Number: | PCT/US95/05219 |
| PCT Publication Date: | November 16, 1995 | PCT Publication Number: | WO95/30670 |
International Family Members for US Patent 5,852,195
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 236894 | Start Trial | |||
| Australia | 2368699 | Start Trial | |||
| Australia | 2462695 | Start Trial | |||
| Australia | 701965 | Start Trial | |||
| Australia | 718117 | Start Trial | |||
| Brazil | 9507615 | Start Trial | |||
| Canada | 2187523 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
